3,3 ',5-Triiodothyroacetic Acid (Triac) Induces Embryonic Zeta-Globin Expression Via Thyroid Hormone Receptor Alpha

Huiqiao Chen,Zixuan Wang,Shanhe Yu,Xiao Han,Yun Deng,Fuhui Wang,Yi Chen,Xiaohui Liu,Jun Zhou,Jun Zhu,Hao Yuan
DOI: https://doi.org/10.1186/s13045-021-01108-z
IF: 28.5
2021-01-01
Journal of Hematology & Oncology
Abstract:The human zeta-globin gene (HBZ) is transcribed in primitive erythroid cells only during the embryonic stages of development. Reactivation of this embryonic globin synthesis would likely alleviate symptoms both in alpha-thalassemia and sickle-cell disease. However, the molecular mechanisms controlling zeta-globin expression have remained largely undefined. Moreover, the pharmacologic agent capable of inducing zeta-globin production is currently unavailable. Here, we show that TRIAC, a bioactive thyroid hormone metabolite, significantly induced zeta-globin gene expression during zebrafish embryogenesis. The induction of zeta-globin expression by TRIAC was also observed in human K562 erythroleukemia cell line and primary erythroid cells. Thyroid hormone receptor alpha (THRA) deficiency abolished the zeta-globin-inducing effect of TRIAC. Furthermore, THRA could directly bind to the distal enhancer regulatory element to regulate zeta-globin expression. Our study provides the first evidence that TRIAC acts as a potent inducer of zeta-globin expression, which might serve as a new potential therapeutic option for patients with severe alpha-thalassemia or sickle-cell disease.
What problem does this paper attempt to address?